Arbaclofen - AGI Therapeutics

Drug Profile

Arbaclofen - AGI Therapeutics

Alternative Names: AGI-006; R-baclofen - AGI Therapeutics

Latest Information Update: 15 May 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AGI Therapeutics
  • Class Aminobutyric acids; Gastrokinetics; Muscle relaxants; Small molecules
  • Mechanism of Action GABA B receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Gastro-oesophageal reflux; Gastroparesis; Nausea and vomiting
  • Discontinued Non-ulcer dyspepsia

Most Recent Events

  • 15 May 2014 No development reported - Preclinical for Gastro-oesophageal reflux in Europe (PO)
  • 15 May 2014 No development reported - Preclinical for Gastroparesis in Europe (PO)
  • 15 May 2014 No development reported - Preclinical for Nausea and vomiting in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top